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Aim: To investigate systematic changes in dose arising when treatment plans optimised using the Anisotropic
Analytical Algorithm (AAA) are recalculated using Acuros XB (AXB) in patients treated with definitive
chemoradiotherapy (dCRT) for locally advanced oesophageal cancers.
Background: We have compared treatment plans created using AAA with those recalculated using AXB. Although
the Anisotropic Analytical Algorithm (AAA) is currently more widely used in clinical routine, Acuros XB (AXB) has
been shown to more accurately calculate the dose distribution, particularly in heterogeneous regions. Studies to
predict clinical outcome should be based on modelling the dose delivered to the patient as accurately as possible.
Methods: CT datasets from ten patients were selected for this retrospective study. VMAT (Volumetric modulated
arc therapy) plans with 2 arcs, collimator rotation ± 5-10° and dose prescription 50 Gy / 25 fractions were created
using Varian Eclipse (v10.0). The initial dose calculation was performed with AAA, and AXB plans were created by
re-calculating the dose distribution using the same number of monitor units (MU) and multileaf collimator
(MLC) files as the original plan. The difference in calculated dose to organs at risk (OAR) was compared using
dose-volume histogram (DVH) statistics and p values were calculated using the Wilcoxon signed rank test. The
potential clinical effect of dosimetric differences in the gross tumour volume (GTV) was evaluated using three
different TCP models from the literature.
Results: PTV Median dose was apparently 0.9 Gy lower (range: 0.5 Gy - 1.3 Gy; p < 0.05) for VMAT AAA plans re-
calculated with AXB and GTV mean dose was reduced by on average 1.0 Gy (0.3 Gy −1.5 Gy; p < 0.05). An apparent
difference in TCP of between 1.2% and 3.1% was found depending on the choice of TCP model. OAR mean dose
was lower in the AXB recalculated plan than the AAA plan (on average, dose reduction: lung 1.7%, heart 2.4%).
Similar trends were seen for CRT plans.
Conclusions: Differences in dose distribution are observed with VMAT and CRT plans recalculated with AXB
particularly within soft tissue at the tumour/lung interface, where AXB has been shown to more accurately
represent the true dose distribution. AAA apparently overestimates dose, particularly the PTV median dose and
GTV mean dose, which could result in a difference in TCP model parameters that reaches clinical significance.* Correspondence: samantha.warren@oncology.ox.ac.uk
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Definitive chemoradiation (dCRT) plays an important
role in the treatment of oesophageal cancer: for both squa-
mous cell and non-operable adenocarcinoma patients, it
offers a clear benefit compared to single modality treat-
ment [1]. Recent evidence also suggests a survival benefit
when CRT is used pre-operatively [2]. However, risks of
local recurrence are high, with a recent study demonstrat-
ing that around 75% of recurrences in dCRT occur in the
primary tumour [3], and improvement of loco-regional
control appears to be a key factor in successful treatment
for these patients. The introduction of advanced radiother-
apy techniques, such as intensity modulation, has gener-
ated a renewed interest in dose escalation for oesophageal
cancer, as delivery of a higher dose to the primary tumour,
whilst maintaining dose to surrounding organs at risk at
safe levels, may now be possible [4,5]. A systematic review
of pre-operative CRT by Geh suggested that a radiation
dose response exists for oesophageal cancer, and therefore
that pathological tumour response would be improved if
the radiotherapy dose were increased above ~ 50 Gy [5,6].
An investigation of the dose response would be supported
by accurate knowledge of the dose delivered to the
tumour. The dose delivered to normal tissues, such as
lung and heart, will also be important in determining the
extent of dose escalation possible for these patients.
A critical component in the analysis of the dose–re-
sponse of oesophageal tumours is therefore the accuracy
of the calculation of the dose distribution, which can be
particularly challenging in the case of thoracic tumours,
due to the presence of low density lung tissue surround-
ing the target volume. Advanced (‘type b’) dose calcula-
tion algorithms (such as AAA - Anisotropic Analytical
Algorithm from Varian) now routinely available in com-
mercial treatment planning systems show improved ac-
curacy compared to the previous pencil beam (‘type a’)
algorithms, but significant errors still persist at the lung/
soft tissue interface, particularly in the re-build-up re-
gion [7,8]. The Acuros (AXB) algorithm, recently intro-
duced in the Eclipse treatment planning system (Varian
Medical Systems, Palo Alto, USA) [9] iteratively solves
the Linear Boltzman Transport Equation and has been
demonstrated to show equivalent accuracy to Monte
Carlo calculations in heterogeneous media [10,11]. Pre-
vious studies comparing the use of AXB vs AAA for cal-
culating dose in patients, e.g. for breast [12], lung
[13-15], and nasopharynx [16] have shown that significant
differences in the calculated dose deposition may arise
when the planning target volume (PTV) encompasses a
range of tissue types, or is close to the interface between
different density materials. Observed differences in mean
PTV dose are up to 1.2% in lung [13], 1.6% in muscle [12]
and 2% in bone [16], where differences in minimum PTV
dose of up to 4% have been observed [16].This study therefore seeks to compare the AXB and
AAA dose calculation algorithms specifically for radio-
therapy planning of thoracic oesophageal tumours, where
the radiation dose in the lung/soft tissue interface region




10 patients with mid-oesophageal cancer treated with
definitive chemoradiotherapy were identified retrospect-
ively. In conformance with our institutional consent pro-
cedure, all patients prospectively gave written consent
for their imaging data to be used for education and
research purposes. This work was approved as part of
on-going radiotherapy physics projects by the appropri-
ate local review board. CT images with IV contrast were
acquired with a slice thickness of 2.5 mm during ‘quiet’
breathing and imported into Eclipse v10 for contouring
and treatment planning. Gross tumour volume (GTV)
including primary tumour and nodal disease was delin-
eated with the aid of PET/CT and endoscopic ultrasound
where available. Margins of 10 mm axially and 20 mm
superior/inferior were added to create the clinical target
volume (CTV), and the PTV was generated by adding a
10 mm margin in all directions according to institutional
protocol. For the studied patient subset, the mean PTV
was 337 cm3 (range 140–658 cm3). The PTV was further
divided into soft tissue ‘PTV_tissue’ and ‘PTV_lung’
where the PTV intersected with lung tissue. Normal tis-
sues (heart, lungs, liver and cord) were delineated, with
an additional planning organ at risk (CordPRV) volume
created using a 5 mm margin around the cord.
Conformal (3D) and RapidArc (RA) treatment plans
were calculated for each patient with a 2.5 mm isotropic
dose grid, a dose prescription of 50 Gy/25 fractions and
were initially optimised using AAA version 10.0.28 with
the aim of covering 95% of PTV with the 95% isodose
contour. 3D_AAA plans consisted of 3–4 beams (anterior,
two lateral oblique and post), normalised to 50 Gy at the
reference point. RA_AAA plans of 2 full arcs with collima-
tor rotation ± 5-10° and were normalised so that the me-
dian PTV dose was 50 Gy. AXB plans (3D_AXB and
RA_AXB) were then re-calculated as dose to medium with
Acuros version 10, using the same MU and MLC as for the
AAA plans. The re-calculated AXB plan is believed to be a
more accurate representation of the dose delivered to the
patient compared to the AAA optimised treatment plans
currently used in clinical routine.
Plan analysis
Dose-volume parameters for target volumes (GTV mean
dose, PTV D95%, PTV median and PTV max dose and
mean dose for PTV_Lung and PTV_tissue) were
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dose metrics (CordPRV Dmax, Lung mean dose and
V20Gy, heart mean dose, V25Gy and V40Gy and liver mean
dose) were recorded. The values for 3D_AAA vs
3D_AXB and RA_AAA vs RA_AXB plans were com-
pared using the Wilcoxon signed rank test, where aver-
age differences between the paired datasets are specified
as median, (range: min - range: max) with p < 0.05 taken
as significant. Tumour control probability (TCP) for the
primary tumour was calculated for all plans via the dif-
ferential DVH for the GTV exported in bins of 0.25 Gy,
using 3 different models taken from the literature
(Figure 1).
Briefly, the Geh TCP [6] model is logistic regression fit
to pathological complete response data from 26 chemo-
radiotherapy trials for pre-operative oesophageal cancer:
TCP zð Þ ¼ exp zð Þ
1þ exp zð Þ
and where the protocol prescribed doses of radiother-
apy and chemotherapy (5FU and cisplatin) were used as
variables:
z ¼ a0 þ a1 total RT doseþ a2 total RT dose
dose per fraction þ a3 duration þ a4 age
þa5 5FU doseþ a6 cisplatin dose
The Bedford TCP [17] calculation uses the Webb-
Nahum model [18] which assumes a normal distribution
of α the LQ parameter, with standard deviation σα. Values
used are σα = 0.08 Gy
−1 and α = 0.40 Gy−1 chosen to fit ob-
served local control rates for oesophageal cancer [19]. An
alternative linear LQ TCP model (Isaacson [20]) using his-
torical data (prior to the CT radiotherapy planning era) has
also been used, although uncertainties in the dose distribu-
tion data for this model means the absolute TCP values
may be less relevant to current chemoradiotherapy treat-
ments, it is included for comparison of predicted relative
differences in TCP.Figure 1 Comparison of TCP models for oesophagus based on
published parameters from different studies.Results
Dose to GTV/PTV
A comparison of the dose distribution for RapidArc
plans calculated using the AAA and AXB dose algo-
rithms for a patient with a PTV of 529 cm3 is shown in
Figure 2, indicating the lower dose obtained with the
more accurate AXB dose calculation algorithm, particu-
larly in the interior of the PTV. The differences in dose
to GTV, and to the lung and tissue components of the
PTV, are given in Table 1 (averaged across all ten pa-
tients). It appears that less dose is actually delivered to
GTV when re-calculated using AXB, as compared to the
dose predicted by AAA. For RA plans, the difference in
mean dose to GTV is on average 1.0 Gy (0.3 - 1.5 Gy;
p < 0.05) and the difference in PTV median dose is on
average 0.9 Gy (0.5 – 1.3 Gy; p < 0.05). As shown in
Table 1 and Figure 3, the difference in calculated dose to
the PTV_Lung tissue using AAA or AXB for RapidArc
plans is not statistically significant. However, a difference
of (on average) 0.9 Gy [0.5 – 1.3 Gy] less dose in the soft
tissue region of the PTV (PTV_tissue) is found when
using the AXB algorithm as compared to AAA. This
indicates that the difference in the two dose calculation
algorithms is more than a simple MU normalisation fac-
tor, and can lead to differences in relative dose distribu-
tion. Similar results for 3D conformal plans are shown
in Tables 1 and 2, indicating the same apparent overesti-
mation of dose to the soft tissue components of the
target when calculated with the AAA algorithm.
Dose-volume histogram analysis/OAR
For every patient, OAR mean dose was also lower in the
AXB recalculated plan than the AAA plan with the aver-
age dose difference (quoted as a percentage of the abso-
lute value calculated with AAA) for RA plans as follows:
lung 1.7%, heart 2.4% (Table 2) 3D CRT plans gave simi-
lar results (Table 2). The average difference in the vol-
ume of heart receiving a moderate dose (V25 Gy) was
5.7% and the higher dose volume in the heart (V40 Gy)
was also significantly less by 3.6% on average for the
RA_AXB dose calculation algorithm compared to the
RA_AAA plan. 3D CRT plans showed a greater differ-
ence (of up to 18.4% for one patient) for heart V40Gy
with AXB. The CordPRV dose showed a significant re-
duction, on average of 3.0% for RA and 2.0% for 3D
CRT, when re-calculated using the AXB dose algorithm
to obtain a more accurate representation of the dose
truly delivered to each patient.
TCP analysis
An apparent difference in TCP expressed here as median
[range: min, range: max] was found for all patients when
re-calculating plans using AXB, due to the apparent
overestimation of GTV dose by AAA. The magnitude of
Figure 2 Comparison of dose distribution calculated using AAA and AXB dose calculation algorithms for mid-oesophageal cancer.
Left: Coronal slice of RapidArc plan calculated using AAA showing the dose distribution for a mid-oesophageal cancer patient with the largest
proportion of lung tissue in the PTV (red contour, total size of 529 cm3). The dose colour scale ranges from 75% (blue) to 102% (red) of the
prescribed dose of 50 Gy. Right: The same RapidArc plan recalculated using the AXB dose calculation algorithm (for the same patient, with the
same dose scale) showing a reduction in dose, particularly in soft tissue in the interior of the PTV.
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Geh predicted a 1.2% [−0.4%, +1.9%] difference in local
control from (RA_AAA) to (RA_ AXB) (p < 0.05), and
the Bedford TCP model predicts a reduction of 3%
[1.1%, 4.5%] from (RA_AAA) to (RA_ AXB) (p < 0.05).
Similar values are seen for the 3D CRT plans: TCP GehTable 1 Comparison of target volume dose calculated
using AAA or AXB for all patients for a) RapidArc plans
and b) 3D conformal radiotherapy (CRT) plans
a)
Target (dose metric) Mean dose [min, max] in Gy p
RA_AAA RA_AXB
CRT_AAA CRT_AXB
GTV (mean) 49.9 [49.6, 50.0] 48.8 [48.3, 49.6] 0.01
PTV (D95%) 48.7 [48.0, 49.1] 47.7 [47.1, 48.2] 0.01
PTV (median) 50.0 (normalisation) 49.1 [48.7, 49.5] 0.01
PTV (max) 52.3 [51.5, 53.1] 53.1 [52.5, 53.9] 0.01
PTV_Lung (mean) 49.6 [49.2, 49.8] 49.7 [49.0, 50.1] 0.18
PTV_tissue (mean) 49.9 [49.8, 50.0] 49.0 [48.7, 49.5] 0.01
b)
Target (dose metric) Mean dose [min, max] in Gy p
CRT_AAA CRT_AXB
GTV (mean) 50.6 [49.8, 51.2] 49.6 [49.0, 50.1] 0.01
PTV (D95%) 48.2 [45.7, 49.4] 47.4 [44.9, 48.6] 0.01
PTV (median) 50.2 [49.6, 50.7] 49.2 [48.1, 49.7] 0.01
Norm point 50.0 (normalisation) 48.8 [48.0, 49.7]
PTV (max) 52.9 [51.9, 53.8] 53.4 [52.4, 54.8] 0.01
PTV_Lung (mean) 49.4 [47.8, 50.3] 49.4 [47.7, 50.7] 0.12
PTV_tissue (mean) 50.2 [49.5, 50.7] 49.2 [48.4, 49.8] 0.01(CRT_AXB) is 1.4% [0.5%, 1.9%] different from the
CRT_AAA mean TCP and Bedford CRT_AAA mean
TCP changes by 3.1% [1.3%, 4.3%]. The Isacsson model
TCP was 1.8% [0.7%, 2.7%] lower for both RA and CRT
plans when comparing AXB to the AAA dose calcula-
tion algorithm.
Discussion
This study compared the dose distributions obtained by
two different dose calculation algorithms (AXB and
AAA) for mid-oesophageal tumours. Lower doses were
found when re-calculating AAA treatment plans with
the AXB algorithm, and this dose difference was clinic-
ally significant for the GTV, PTV and certain organs at
risk (heart, cord). The lower doses predicted by AXBFigure 3 Differential DVH for GTV and PTV using AAA and AXB
dose calculation algorithms.
Table 2 Mean % dose difference (quoted as a percentage
of the absolute value calculated with AAA) to organs at
risk calculated using AAA or AXB for a) RapidArc plans
and b) 3D conformal radiotherapy (CRT) plans
a)
OAR and dose metric Mean difference [min, max]
% (RA_AAA) – (RA_AXB)
p
Cord PRV Dmax −3.0% [−3.9%, −1.6%] <0.05
Lung Mean −1.7% [−5.2%, −0.4%] <0.05
Lung V20Gy −2.7% [−8.3%, 0.0%] <0.05
Heart Mean −2.4% [−3.0%, −1.2%] <0.05
Heart V25Gy −5.7% [−7.4%, −4.5%] <0.05
Heart V40Gy −3.6% [−8.3%, −1.3%] <0.05
Liver Mean −1.2% [−2.2%, 0.0%] NS
b)
OAR and dose metric Mean difference [min, max]
% (CRT_AAA) – (CRT_AXB)
p
Cord PRV Dmax −2.0% [ −8.2%, 2.7%] <0.05
Lung Mean −2.2% [ −4.5%, 0.3%] <0.05
Lung V20Gy −1.5% [ −3.7%, 0.4%] <0.05
Heart Mean −2.6% [ −3.4%, −1.7%] <0.05
Heart V25Gy −3.0% [−12.4%, −0.3%] <0.05
Heart V40Gy −6.9% [−18.4%, −2.2%] <0.05
Liver Mean −1.5% [ −2.5%, 0.6%] NS
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RapidArc plans, indicating that the differences in dose
distribution for oesophageal cancer are not dependent
on the beam delivery technique. This is in line with re-
sults from the literature, for example for lung tumours,
where AXB predicts up to 1.1 Gy less than AAA to the
soft tissue in the PTV for 3D, IMRT and RA plans [13].
Previous studies investigating the use of AXB in hetero-
geneous media [10,11,14] suggest that this algorithm is
more accurate than the widely-used AAA, especially at
the lung/soft tissue interface region [13,21,22]. In par-
ticular, AXB shows a much better agreement with
Monte Carlo calculations [23] or dose measurements
[24] in regions of re-buildup in soft tissue after the beam
has passed through low density tissue such as lung or
air. Our AXB results can therefore be considered as a
better approximation of the true dose distribution than
data obtained using AAA, and indicate an apparent over-
estimation of dose to the primary tumour of around 1 Gy
when calculated with AAA. The location of the dose
over-estimation is particularly pertinent in the case of
oesophageal cancers, where most local recurrences occur
within the GTV, well inside the treatment field.
However, as most clinical outcome data is based on dose
distribution calculated using “type b” (AAA) or “type a”
(pencil beam) dose algorithms, the interpretation of these
results in the context of current radiotherapy treatmentsand future dose escalation trials should be carefully ana-
lysed. Normalisation of 3D CRT radiotherapy treatment
plans using AXB to meet the protocol dose prescription of
50 Gy would result in an increase in MU of around 2%
(range 1.0% to 2.8%), with a corresponding increase in
mean dose delivered to the surrounding normal tissues
contained within the Body-PTV contour.
Alternative methods to account for the differences in
dose distribution include creation of algorithm-specific
radiobiological parameters, such as TCP models of local
control in breast cancer with specific pencil beam, AAA
or AXB parameters [25]; or re-analysis of the fitting pa-
rameters to take into account the improved dose calcu-
lation. This latter approach has been used in a study of
dose-volume effects in radiation pneumonitis used for
NTCP modelling of toxicity in lung [26]. The absolute
TCP values from the Geh and Bedford models were
broadly consistent at ~37%. The smaller TCP difference
predicted by the Geh model (1.2% vs. 3% for Bedford) is
likely to be due to the fact that the Geh model was de-
rived from more heterogeneous population data.
It should be noted that optimisation of RA plans using
AXB will, or course, produce plans which meet the pre-
scribed dose constraints, but have a different MLC flu-
ence. We have shown that this is not simply a scaled
version of the AAA result (data not shown). One limita-
tion of our current study is that we have compared dose
distributions calculated using the planning CT dataset
acquired during free-breathing. Studies using 4D-CT
scans for dose accumulation throughout the respiratory
cycle suggest that the dosimetric effect of movement is
slight, even for small tumours entirely surrounded by
low density lung [27]. The cranial-caudal location of the
primary tumour in mid-oesophageal cancers can also be
difficult to identify, although an analysis of fiducial marker
movement during 4D-CT scans for mid-oesophageal can-
cer suggested 95% of intra-fractional tumour movement
would be covered by a 7.4 mm margin in the cranial-
caudal direction, and this is within our CTV to PTV mar-
gin of 10 mm. Variations in inter-fractional displacement
have also been investigated using repeated 4D-CT scans
[28], and indicate a general trend for tumour regression
during the course of radiotherapy, but no systematic dis-
placement was observed for mid-oesophageal tumours
even after 20 fractions of radiotherapy treatment.
Conclusions
Recalculating treatment plans for mid-oesophageal can-
cer using the more accurate AXB dose calculation algo-
rithm instead of AAA produces a lower dose to the PTV
and GTV, and lower mean dose to the surrounding or-
gans at risk. The difference in dose is largest in areas of
soft tissue surrounded by low density lung (such as the
oesophageal primary tumour volume and the heart).
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specify the dose calculation algorithm used, in order to
avoid bias in the generation of dose-volume constraints
and radiobiological model parameters.
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